Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron gets ready to begin clinical trial of new drug candidate

CDI causes an estimated annual economic cost of more than US$10 billion.
Immuron gets ready to begin clinical trial of new drug candidate
Phase 1/2 clinical trial of IMM-529 to start by the end of Q2 2017

Immuron (ASX:IMC) has successfully manufactured trial supplies of its clinical candidate IMM-529, an oral immunotherapeutic targeting the prevention of clostridium difficile Infection (CDI).

CDI results from disruption of normal, healthy bacteria in the colon, often as a result of antibiotics.

IMM-529 is a biological product which is intended to prevent and treat CDI without destroying the microbiome like antibiotic treatments, allowing the microbiome to return to a healthy state.

The antibodies survive transit through the stomach and remain functional in the large intestine.

IMM-529 was manufactured by the Commonwealth Scientific and Industrial Research Organisation (CSIRO) Separations Science team and Pharmaceutical Packaging Professionals.

Human safety and efficacy studies (Phase 1/2 clinical trial) of IMM-529 will start by the end of Q2 2017, and will aim to build on positive pre-clinical results.

These results were reported from a series of proof-of-concept efficacy studies completed by Dr. Dena Lyras and her research team at the Monash University in Melbourne.

CDI has become a major-medical problem causing an estimated annual economic cost of more than US$10 billion globally.

The problem is especially acute in hospitals and in long-term in-patient care facilities.

An estimated 29,000 patients die each year from CDI in the U.S. alone. Recurrent CDI affects circa 100,000 people in the U.S. annually.

Immuron’s share price has more than doubled since the start of 2017, last trading at $0.55.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use